Melanoma March Update
13 March 2020
MELANOMA MARCH - CANCELLATION OF EVENTS
Statement from Melanoma Institute Australia CEO Matthew Browne
Due to the escalating impact of COVID-19, and in the interests of the health and safety of all participants and attendees, we have made the difficult decision to cancel all remaining Melanoma March events nationally. This includes the seven events scheduled for this weekend - Melbourne, Bunbury, Bendigo, Coolangatta, Macarthur, Mackay, and Wagga Wagga.
This decision has not been made lightly, however protecting the health of our dedicated community members and their families who run and attend these events, many of whom are cancer patients, is paramount.
We will be offering full refunds for registrations. (See below).
We are planning to hold a virtual Melanoma March event on Sunday 29th March to enable our community across Australia to still come together as we have done for Melanoma March for the last 9 years. We will provide more detail regarding this very soon.
My sincere apologies and thanks particularly to our volunteer committees who work tirelessly to put on their local Melanoma March events every year.
UPDATE ON REFUNDS
If you would like a refund for your Melanoma March event registration, please email email@example.com. Otherwise, all registration fees will go towards our overall Melanoma March tally. We are of course still gratefully accepting donations on the Melanoma March website to support development of the national matched immunotherapy platform. Your ongoing support and understanding is greatly appreciated.
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.